Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

A. Stein, Evan; Mellis, Scott; D. Yancopoulos, George; Stahl, Neil; Logan, Douglas; Smith, William; Lisbon, Eleanor; J. Gutiérrez, María; Webb, Cheryle; Wu, Richard; Du, Yunling; Kranz, Therese; Gasparino, Evelyn; D. Swergold, Gary

doi:10.1056/nejmoa1105803

Public

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Published in New England Journal of Medicine • Mar 22, 2012

Authors:

Evan A. Stein

Scott Mellis

George D. Yancopoulos

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated ...

Subject

PCSK9

Kexin

Subtilisin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!